Next generation antibody therapeutics: Antibody fragments, dual-targeting strategies, and beyond…
A multitude of novel therapeutic antibody formats based on modification…
9 October 2009 | By Dr Martin Scott, Molecular Cell Biologist, Biopharm R&D, GlaxoSmithKline and Dr Neil Clarke, Molecular Cell Biologist and Biology Section Leader, Biopharm R&D, GlaxoSmithKline
A multitude of novel therapeutic antibody formats based on modification of the conventional IgG format have arisen in recent years. The intensification of interest in this area reflects a pressing need for an additional repertoire of therapeutic molecules which retain the exquisite binding specificity and low intrinsic toxicity of monoclonal…